Quantitative structure-activity studies on a series of igrastatin analogs as inhibitors of cancer cell metastasis

Medicinal Chemistry

Volumn 7, Issue 3, 2011, Pages 155-164

  Santos, Ricardo N ^a   Guido, Rafael V C ^a   Oliva, Glaucius ^a   Dias, Luiz C ^b   Andricopulo, Adriano D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cancer; Drug design; Metastasis; Migrastatin; QSAR

Indexed keywords

ANTIMETASTATIC AGENT; ISOMIGRASTATIN DERIVATIVE; MIGRASTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENCY; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CELL MOVEMENT; DATABASES, FACTUAL; MACROLIDES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PIPERIDONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM;

EID: 79955751500     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340611795564240     Document Type: Article

References (29)

1. Bode, A.M.; Dong, Z. Cancer prevention research-then and now. Nat. Rev. Cancer, 2009, 9, 508-516.
2. Hedley, B.D.; Winquist, E.; Chambers, A.F. Therapeutic targets for antimetastatic therapy. Expert. Opin. Ther. Targets, 2004, 8, 527-536. (Pubitemid 40028364)
3. Nakae, K.; Yoshimoto, Y.; Sawa, T.; Homma, Y.; Hamada, M.; Takeuchi, T.; Imoto, M. Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1 taxonomy, fermentation, isolation and biological activities. J. Antibiot., 2000, 53, 1130-1136.
4. Woo, E.J.; Starks, C.M.; Carney, J.R.; Arslanian, R.; Cadapan, L.; Zavala, S.; Licari, P. Migrastatin and a new compound, isomigrastatin, from Streptomyces platensis. J. Antibiot., 2002, 55, 141-146.
5. Ju, J.; Rajski, S.R.; Lim, S.; Seo, J.; Peters, M.R.; Hoffmann, F.M.; Shen, B. Lactimidomycin, iso-migrastatin and related glutarimidecontaining 12-membered macrolides are extremely potent inhibitors of cell migration. J. Am. Chem. Soc., 2009, 131, 1370-1371.
6. Gaul, C.; Njardarson, J.T.; Shan, D.; Dorn, D.C., Wu, K.; Tong, W.P.; Huang, X.; Moore, M.A.S.; Danishefsky, S.J. The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. J. Am. Chem. Soc., 2004, 126, 11326-11337. (Pubitemid 39223205)
7. Njardarson, J.T.; Gaul, C.; Shan, D.; Huang, X.; Danishefsky, S.J. Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (+)-migrastatin. J. Am. Chem. Soc., 2004, 126, 1038-1040.
8. San, D.; Chen, L.; Njardarson, J.T.; Gaul, C.; Ma, X.; Danishefsky, S.J.; Huang, X. Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice. Proc. Natl. Acad. Sci. USA, 2005, 102, 3772-3776. (Pubitemid 40354687)
9. Dias, L.C.; Finelli, F.G.; Conegero, L.S.; Krogh, R.; Andricopulo, A.D. Synthesis of the macrolactone of migrastatin and analogs with potent cell migration inhibitory activity. Eur. J. Org. Chem., 2010, 10, 6748-6759.
10. Chen, L.; Yang, S.; Jakoncic, J.; Zhang, J.J.; Huang, X. Migrastatin analogues target fascin to block tumour metastasis. Nature, 2010, 464, 1062-1066.
11. Guido, R.V.C.; Oliva, G.; Montanari, C.A.; Andricopulo, A.D. Structural basis for selective inhibition of trypanosomatid glyceraldehyde- 3-phosphate dehydrogenase: molecular docking and 3D QSAR studies. J. Chem. Inf. Model., 2008, 48, 918-929. (Pubitemid 351757757)
12. Guido, R.V.C.; Oliva, G.; Andricopulo, A.D. Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem., 2008, 15, 37-46. (Pubitemid 351234626)
13. Andricopulo, A.D.; Yunes, R.A.; Nunes, R.J.; Savi, A.O.S.; Correa, R.; Cruz, A.B.; Cechinel, V. Synthesis and antibacterial activity of cyclic imides: 3,4-dichloromaleimides and 3-chloro-4-substitutedmaleimides. Quim. Nova, 1998, 21, 573-577. (Pubitemid 128548746)
14. Andricopulo, A.D.; Salum, L.B.; Abraham, D.J. Structure-based drug design strategies in medicinal chemistry. Curr. Top. Med. Chem., 2009, 9, 771-790.
15. Lima, E.O.; Queiroz, E.F.; Andricopulo, A.D.; Nunes, R.J.; Yunes, R.A.; Correa, R.; Cechinel, V. Evaluation of antifungal activity of N-aryl-maleimides and N-phenylalkyl-3,4-dichloromaleimides. Bol. Soc. Chil. Quim., 1999, 44, 185-189.
16. Salum, L.B.; Andricopulo, A.D. Fragment-based drug design strategies in medicinal chemistry. Expert. Opin. Drug. Discov., 2010, 5, 405-412.
17. Salum, L.B.; Polikarpov, I.; Andricopulo, A.D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. J. Chem. Inf. Model., 2008, 48, 2243-2253.
18. Tripos Inc., HQSAR Manual Release in SYBYL 8.0, St. Louis, MO, 2008.
19. Salum, L.B.; Dias, L.C.; Andricopulo, A.D. Fragment-based QSAR and molecular modeling studies on a series of discodermolide analogs as microtubule-stabilizing anticancer agents. QSAR Comb. Sci., 2009, 28, 325-337.
20. Hashimoto, Y.; Shimada, Y.; Kawamura, J.; Yamasaki, S.; Imamura, M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology, 2004, 67, 262-270. (Pubitemid 39551711)
21. Honorio, K.M.; Garratt, R.C.; Polikarpov, I.; Andricopulo, A.D. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. J. Mol. Graphics Modell., 2007, 25, 921-927. (Pubitemid 46223544)
22. Guido, R.V.C.; Castilho, M.S.; Mota, S.; Oliva, G.; Andricopulo, A.D. Classical and hologram QSAR studies on a series of inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. QSAR Comb. Sci., 2008, 27, 768-781.
23. Moda, T.L.; Montanari, C.A.; Andricopulo, A.D. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg. Med. Chem., 2007, 15, 7738-7745. (Pubitemid 47575914)
24. Castilho, M.S.; Guido, R.V.C.; Andricopulo, A.D. Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. Bioorg. Med. Chem., 2007, 15, 6242-6252. (Pubitemid 47088952)
25. Jain, A. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided. Mol. Des., 2007, 21, 281-306. (Pubitemid 46630055)
26. Oskarsson, T.; Nagorny, P.; Krauss, I.J.; Perez, L.; Mandal, M.; Yang, G.; Ouerfelli, O.; Xiao, D.; Moore, M.A.S.; Massagu, J.; Danishefsky, S.J. Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis. In vivo and mechanistic studies on the migrastatin core ether analog. J. Am. Chem. Soc., 2010, 132, 3224-3228.
27. Hashimoto, Y.; Skacel, M.; Adams, J.C. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int. J. Biochem. Cell Biol., 2005, 37, 1787-1804. (Pubitemid 40961664)
28. Yoder, B.J.; Tso, E.; Skacel, M.; Pettay, J.; Tarr, S.; Budd, T.; Tubbs, R.R.; Adams, J.C.; Hicks, D.G. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptornegative breast cancer and a more aggressive clinical course. Clin. Cancer Res., 2005, 11, 186-192. (Pubitemid 40075794)
29. Minn, A.J.; Gupta, G.P.; Siegel, P.M.; Bos, P.D.; Shu, W.; Giri, D.D.; Viale, A.; Olshen, A.B.; Gerald, W.L.; Massagué, J. Genes that mediate breast cancer metastasis to lung. Nature, 2005, 436, 518-524. (Pubitemid 41112921)